Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Goodrich

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Molecular Cancer Research : MCR|April 27, 2025
Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular VesiclesCandice L Bizzaro, Camila A Bach, Ricardo A Santos, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progressionSilvia D Rodrigues, Caroline Fidalgo Ribeiro, Giuseppe N Fanelli, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticityLetian Zhang, Meenalakshmi Chinnam, Bradley Balk, et al.
The Journal of Clinical Investigation|July 18, 2024
Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancerSheng-Yu Ku, Yanqing Wang, Maria Mica Garcia, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 1, 2025
An Agrin-YAP/TAZ Rigidity Sensing Module Drives EGFR-Addicted Lung TumorigenesisReza Bayat Mokhtari, Divyaleka Sampath, Paige Eversole, et al.
Scientific Reports|November 7, 2022
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancerFabio Quaglia, Shiv Ram Krishn, Khalid Sossey-Alaoui, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient SurvivalXiaozhuo Liu, Eduardo Cortes, Yibing Ji, et al.
Science (New York, N.Y.)|January 7, 2017
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancerPing Mu, Zeda Zhang, Matteo Benelli, et al.
Nature Reviews. Cancer|June 3, 2025
Acquired resistance in cancer: towards targeted therapeutic strategiesAlice Soragni, Erik S Knudsen, Thomas N O'Connor, et al.
Nature Communications|November 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancerShankha S Chatterjee, Juan F Linares, Tania Cid-Diaz, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Molecular Cancer Research : MCR|April 27, 2025
Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular VesiclesCandice L Bizzaro, Camila A Bach, Ricardo A Santos, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progressionSilvia D Rodrigues, Caroline Fidalgo Ribeiro, Giuseppe N Fanelli, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticityLetian Zhang, Meenalakshmi Chinnam, Bradley Balk, et al.
The Journal of Clinical Investigation|July 18, 2024
Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancerSheng-Yu Ku, Yanqing Wang, Maria Mica Garcia, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 1, 2025
An Agrin-YAP/TAZ Rigidity Sensing Module Drives EGFR-Addicted Lung TumorigenesisReza Bayat Mokhtari, Divyaleka Sampath, Paige Eversole, et al.
Scientific Reports|November 7, 2022
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancerFabio Quaglia, Shiv Ram Krishn, Khalid Sossey-Alaoui, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient SurvivalXiaozhuo Liu, Eduardo Cortes, Yibing Ji, et al.
Science (New York, N.Y.)|January 7, 2017
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancerPing Mu, Zeda Zhang, Matteo Benelli, et al.
Nature Reviews. Cancer|June 3, 2025
Acquired resistance in cancer: towards targeted therapeutic strategiesAlice Soragni, Erik S Knudsen, Thomas N O'Connor, et al.
Nature Communications|November 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancerShankha S Chatterjee, Juan F Linares, Tania Cid-Diaz, et al.
Pageof 8